Novel Agents in the Treatment of Lung Cancer: Assessing Opportunities for Combination Therapy
Fifth Cambridge Conference
October 2007
Summary Statement Novel Agents in the Treatment of Lung Cancer: Fifth Cambridge Conference Assessing Opportunities for Combination Therapy Thomas J. Lynch Jr; George R. Blumenschein Jr; Jeffrey A. Engelman; Igor Espinoza-Delgado; Ramaswamy Govindan; Jeff Hanke; Nasser H. Hanna; John V. Heymach; Fred R. Hirsch; Pasi A. Janne; Rogerio C. Lilenbaum; Ronald B. Natale; Gregory J. Riely; Lecia V. Sequist; Geoffrey I. Shapiro; Alice Shaw; Frances A. Shepherd; Mark Socinski; A Gregory Sorensen; Heather A. Wakelee; Aaron Weitzman
Antibodies to Vascular Endothelial Growth Factor in Non–Small Cell Lung Cancer
Heather Wakelee
The Current Status and Evolving Role of Sunitinib in Non-small Cell Lung Cancer
Mark A. Socinski
Sorafenib in Lung Cancer: Clinical Developments and Future Directions
George R. Blumenschein, Jr.
Dual Targeting of the Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Pathways With Vandetinib (ZD6474) in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Ronald B. Natale
The Tyrosine Kinase Inhibitor Cediranib for Non–small Cell Lung Cancer and Other Thoracic Malignancies
Petros Nikolinakos and John V. Heymach
Discussion - Anti-VEGF Agents
First-Generation Epidermal Growth Factor Receptor Inhibitors in Non–small Cell Lung Cancer: Clinical Impact of the Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization Assay
Fred. R. Hirsch, Rafal Dziadziuszko, Marileila Varella-Garcia, Wilbur A. Franklin, David R. Gandara, and Paul A. Bunn Jr.
First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in EGFR Mutation: Positive Non–small Cell Lung Cancer Patients
Lecia V. Sequist
Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–small Cell Lung Cancer
Gregory J. Riely
Discussion - EGFR-Targeted Agents
Heat Shock Protein 90 Inhibition in Lung Cancer
Takeshi Shimamura and Geoffrey I. Shapiro
K-ras as a Target for Lung Cancer Therapy
Alex A. Adjei
Immunotherapy for Lung Cancer
Penelope A. Bradbury and Frances A. Shepherd
New Horizons in Chemotherapy: Platforms for Combinations in First-Line Advanced Non–small Cell Lung Cancer
Rogerio C. Lilenbaum
Discussion - Other Lung Cancer Targets
Discussion - Clinical Trials and Combination Therapies in Lung Cancer
